<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631539</url>
  </required_header>
  <id_info>
    <org_study_id>2010-018384-42</org_study_id>
    <nct_id>NCT01631539</nct_id>
  </id_info>
  <brief_title>Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC</brief_title>
  <official_title>Chemoembolisation With Irinotecan Loaded DC Bead (DEBIRI) in Combination With Cetuximab and 5FU/LV in the First Line Treatment of Patients With KRAS Wildtype Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess feasibility of chemoembolization with DC Bead loaded
      with Irinotecan in combination with Cetuximab and 5FU/LV as a first line treatment for
      wildtype KRAS unresectable liver metastases from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 patients will be included. The duration of the trial will be approximately 24 months.

      Every 8 weeks there will be a tumour lesion assessment.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients enrolled
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of chemoembolization with DC Bead loaded with Irinotecan</measure>
    <time_frame>after one cycle = after 8 weeks</time_frame>
    <description>Feasibility of the study by measuring the number of enrolled patients who can finish the first cycle of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 18 months</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemoembolization</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>chemoembolization with DC Bead™ loaded with Irinotecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DC Bead™</intervention_name>
    <description>chemoembolization with DC Bead™ loaded with Irinotecan</description>
    <arm_group_label>Chemoembolization</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly</description>
    <arm_group_label>Chemoembolization</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 FU</intervention_name>
    <description>every 2 weeks IV</description>
    <arm_group_label>Chemoembolization</arm_group_label>
    <other_name>5 fluoro uracyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>every 4 weeks chemoembolization</description>
    <arm_group_label>Chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of stage IV KRAS wild-type colorectal adenocarcinoma, with
             metastases predominantly in the liver (≥80% of tumor burden) that are deemed
             unresectable.

          2. Primary tumour has been treated with complete surgical resection without evidence of
             residual tumour

          3. Patients must have at least 1 measurable lesion (RECIST criteria)

          4. Performance status ECOG 0-1

          5. Aged ≥18 years

          6. Life expectancy &gt; 3 months

          7. No prior chemotherapy for metastatic disease

          8. Hematologic function: WBC ≥ 3.0 x 10*9/L, platelets ≥ 100 x10*9/L

          9. Adequate organ function as measured by:

               -  Serum creatinine £ 1.5 x upper limit of normal (ULN)

               -  Serum transaminases (AST &amp; ALT) £ 5 x ULN

               -  Bilirubin&gt; 1.5 times the upper limit of the normal range

         10. Women of child bearing potential and fertile men are required to use effective
             contraception (negative βHCG for women of child-bearing age)

         11. Signed, written informed consent

         12. Patients with patent main portal vein

         13. Maximum liver involvement ≤60%

        Exclusion Criteria:

          1. Presence of CNS metastases

          2. Contraindications to FU/LV, Irinotecan or Cetuximab

          3. Active bacterial, viral or fungal infection within 72 hours of study entry

          4. Women who are pregnant or breast feeding

          5. Allergy to contrast media or history of severe hypersensitivity to study drugs.

          6. Presence of another concurrent malignancy. Prior malignancy in the last 5 years except
             adequately treated basal or squamous cell skin cancer or carcinoma in situ of the
             cervix

          7. Any contraindication for hepatic embolization procedures:

               -  porto-systemic shunt

               -  hepatofugal blood flow

               -  severe atheromatosis

          8. Contraindication to hepatic artery catheterization, such as a patient with severe
             peripheral vascular disease precluding catheterization

          9. Other significant medical or surgical condition, or any medication or treatment
             regimens, that would place the patient at undue risk, that would preclude the safe use
             of chemoembolization or would interfere with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Cutsem, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Eric Van Cutsem</investigator_full_name>
    <investigator_title>Professor MD PhD Eric Van Cutsem</investigator_title>
  </responsible_party>
  <keyword>chemoembolization</keyword>
  <keyword>DC Bead™</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>5FU/LV</keyword>
  <keyword>KRAS</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

